Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.

Antiviral therapy - 1 Jan 2006

Canestri Ana, Ghosn Jade, Wirden Marc, Marguet Françoise, Ktorza Nadine, Boubezari Imane, Dominguez Stéphanie, Bossi Philippe, Caumes Eric, Calvez Vincent, Katlama Christine

Abstract excerpt

OBJECTIVE: To evaluate the efficacy of foscarnet on HIV infection in patients with late-stage HIV disease and multiple drug resistance. METHODS: Three drugs experienced patients with plasma viral load (pVL) > 50,000 copies/ml and CD4+ T-cell counts < 100/mm3 were eligible for this open-label, single-arm, add-on pilot study. Foscarnet induction therapy consisted of 5 g intravenously twice daily for 6 weeks, in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to Drug Resistance, Multiple, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Foscarnet

Share to HIV Protease Inhibitors

Share to Pilot Projects

Share to Reverse Transcriptase Inhibitors

Share to Salvage Therapy

Source

Identifiers

PMID: 16964823

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.PMID 16964823Read ↗

Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.Semantic proximity Read ↗

Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations.Semantic proximity Read ↗

Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesSemantic proximity Read ↗

Class-sparing regimens for initial treatment of HIV-1 infection.Semantic proximity Read ↗

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.Semantic proximity Read ↗

MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study.Semantic proximity Read ↗

Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile.Semantic proximity Read ↗

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.Semantic proximity Read ↗

Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.Semantic proximity Read ↗

Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.Semantic proximity Read ↗

Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.Semantic proximity Read ↗

Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.